CIBC Asset Management’s Haemonetics HAE Stock Holding History

CIBC Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,870	Closed	-$208K	–	1375
2021 Q1	$208K	Buy	1,870 +3	+0.2%	+$371	﹤0.01%	1226
2020 Q4	$222K	Buy	+1,867	New	+$201K	﹤0.01%	1078
2020 Q1	–	Sell	-1,820	Closed	-$209K	–	1082
2019 Q4	$209K	Sell	1,820 -91	-5%	-$11K	﹤0.01%	1062
2019 Q3	$241K	Hold	1,911	–	–	﹤0.01%	934
2019 Q2	$230K	Buy	+1,911	New	+$188K	﹤0.01%	977
2018 Q4	–	Sell	-1,911	Closed	-$219K	–	1082
2018 Q3	$219K	Buy	+1,911	New	+$198K	﹤0.01%	1014
2018 Q2	–	Sell	-3,613	Closed	-$264K	–	1138
2018 Q1	$264K	Hold	3,613	–	–	﹤0.01%	846
2017 Q4	$210K	Buy	+3,613	New	+$190K	﹤0.01%	990

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

CIBC Asset Management's HAE Position: Q2 2021 in Review

CIBC Asset Management sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 1,870 shares — an estimated $208K sold.

CIBC Asset Management first reported a position in HAE in Q4 2017 and held it in 8 quarters. The position peaked at $264K in Q1 2018. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

CIBC Asset Management reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
CIBC Asset Management sold 1,870 Haemonetics shares in Q2 2021, an estimated $208K.
CIBC Asset Management first reported a position in Haemonetics in Q4 2017 and held it in 8 quarters.
CIBC Asset Management's Haemonetics position peaked at $264K in Q1 2018.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on CIBC Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.